CVT
13/11/2015 10:13
GENERAL
NOT PRICE SENSITIVE
REL: 1013 HRS Comvita Limited
GENERAL: CVT: Derma Sciences Halts Phase III Clinical Trial
Comvita's USA partner, Derma Sciences, Inc., in which Comvita owns 1.098m
shares (4.3%), announced overnight that its clinical trial DSC 127 has been
terminated. This clinical trial is unrelated to the sales programme of
Medihoney products conducted by Derma Sciences. For your information, the
attached Press Release from Derma Sciences to the market, explains.
Ends
For further information:
Scott Coulter, Comvita Chief Executive, Ph. 021 386 988
Neil Craig, Comvita Chair, Ph. 021 731 509
About Comvita (www.comvita.co.nz)
Comvita (NZX:CVT) is a global natural health company committed to the
development of innovative products, backed by ongoing investment in
scientific research. We are the world leaders in Manuka (leptospermum) honey
and fresh-picked Olive Leaf Extract, which are at the core of the Comvita
product range.
We have approximately 50% of honey supply under direct ownership or control,
with the balance of supply from long term contractual and partnership
arrangements. Comvita pioneered the development and use of medical grade
Manuka honey and was the first to receive FDA approval (2007). We partner
with US wound care company Derma Sciences, Inc. (NASDAQ:DSCI), the global
licensee for Medihoney(R) specialist wound care products, which are used in
hospitals and medical centres around the world. Comvita's freshly picked
Olive Leaf Extract is grown, harvested, extracted and bottled at the world's
largest specialised olive leaf grove, with over one million olive trees.
Comvita sells into more than 18 countries through a network of our own
branded retail locations, online (seven country specific e-commerce websites)
and third-party outlets. We have over 500 staff located in New Zealand,
Australia, Hong Kong, Japan, South Korea, the United Kingdom and the USA.
End CA:00273399 For:CVT Type:GENERAL Time:2015-11-13 10:13:49
